Hostname: page-component-7c8c6479df-r7xzm Total loading time: 0 Render date: 2024-03-28T17:50:31.867Z Has data issue: false hasContentIssue false

NICE's restrictions on the use of acetylcholinesterase inhibitors

Published online by Cambridge University Press:  02 January 2018

Simon Thacker
Affiliation:
Kingsway Hospital, Derby DE22 3LZ, email: Simon.Thacker@DerbysMHServices.nhs.uk
Ben Lomas
Affiliation:
Kingsway Hospital
Kate Thacker
Affiliation:
Kingsway Hospital
Rights & Permissions [Opens in a new window]

Abstract

Type
The columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2008

Ganeshalingam et al (Reference Ganeshalingam, Cooper and Livingston2008) infer that prescribers are making clinical judgements rather than strictly adhering to the Mini-Mental State Examination (MMSE) score when deciding to prescribe acetylcholinesterase inhibitors under the revised National Institute for Health and Clinical Excellence guidance (National Institute for Health and Clinical Excellence, 2006).

We examined this issue in Southern Derbyshire by scrutinising application forms submitted by clinicians to our pharmacy department as a prerequisite to the issuing of these drugs.

In the year 1 June 2007 to 30 June 2008, 227 service users were initiated on acetylcholinesterase inhibitors by 7 clinicians working in old age psychiatry and 32 (14%) initiates scored above 20 on the MMSE, of whom 26 had a recorded diagnosis of Alzheimer's disease. Within this high-scoring group of individuals with Alzheimer's disease, MMSE score did not correlate with Bristol Activities of Daily Living (BADL) or Relative Stress Scale (RSS) scores (Spearman's r=0.06 and 0.16 respectively, P>10%), but BADL did correlate with RSS (Spearman's r=0.79, P<1%) - high functional impairment was associated with more carer stress. Almost half (n=12) of the 26 individuals showed such features of dementia as agitation, aggression or psychosis and 11 were anxious, depressed or apathetic. Only six had no recorded behavioural or psychological features of dementia.

These findings indicate that relying on the MMSE score to guide the prescribing of acetylcholinesterase inhibitors to people with apparently mild Alzheimer's disease is likely to represent poor practice. We propose that all individuals with an MMSE of 20 or above are given an acetylcholinesterase inhibitor unless sufficient evidence can be gathered to justify withholding it.

References

Ganeshalingam, Y., Cooper, C. & Livingston, G. (2008) Referral patterns and acetylcholinesterase inhibitor prescribing for cognitive impairment (1999–2007): impact of NICE guidelines. Psychiatric Bulletin, 32, 265267.CrossRefGoogle Scholar
National Institute for Health and Clinical Excellence (2006) Donepezil, Galantamine, Rivastigmine(Review)and Memantine for the Treatment of Alzheimer's Disease (Amended). NICE (http://www.nice.org.uk/TA111).Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.